BIO - Brazilian Information Oncology

423 posts

BIO - Brazilian Information Oncology banner
BIO - Brazilian Information Oncology

BIO - Brazilian Information Oncology

@OncologyBio

Group formed by 6 Brazilian oncologists with scientific excellence in taking care of patients.

Katılım Nisan 2020
306 Takip Edilen618 Takipçiler
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
Controversies about therapies in mUC after #GU23. How many patients receive 1, 2 and 3L therapy? Do we need check FGFR for all? When? 3 or 6 cycles of chemo? Platinum eligibility. Cisplatin fit patients should receive cisplatin or carboplatin is acceptable? @OncologyBio meeting
Andrey Soares tweet media
English
0
3
11
545
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
Discussion about one of the best studies from #GU23. The importance of biomarkers to define who will or will not have benefit of chemotherapy in patients with CSI testicular cancer @OncologyBio meeting @asasse
Andrey Soares tweet media
English
0
2
7
400
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
Amazing data. Should bi-parametric MRI, radiomics and AI increase the detection rate of clinical significant PC in a faster and hopefully cheaper way? #GU23 @ASCO @OncologyBio
Neeraj Agarwal, MD, FASCO@neerajaiims

Abs#390 @ASCO #GU23 by @FatimaKarzai et al👉bit.ly/3XBvJZm MRI screening in men with germline pathogenic variant detects #prostatecancer below conventional PSA thresholds. Potentially a new screening tool in these men @urotoday @PCF_Science @wandering_gu @heatherhcheng

English
0
2
2
603
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
Cabopoint and BIONIKK are interesting studies to help decisions for a 2 line therapy in #RCC while we’re still waiting for phase 3 trials for patients progressing after 1L IO based. #GU23 @ASCO @OncologyBio
Neeraj Agarwal, MD, FASCO@neerajaiims

Abs#606 @ASCO #GU23 by @AlbigesL 👉bit.ly/3lxqcFL: CaboPoint ph2 trial 👉 Cabozantinib efficacious in mRCC #Kidneycancer post progression on CPI-based combination Rx, regardless of 1L regimen @ViktorGruenwald @OncoAlert @kidneycan @KidneyCancer @Uromigos @urotoday

English
0
3
10
1.2K
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
Starting #GU23 with an outstanding review about 1L treatment of #RCC and an interesting spoiller about what we’ll see at #GU23 about #RCC with @BourlonMaite during a @OncologyBio meeting
Andrey Soares tweet media
English
1
4
32
5.9K
BIO - Brazilian Information Oncology retweetledi
Fernando Sabino, MD, PhD
Fernando Sabino, MD, PhD@fsabino_onco·
Congrats to @neerajaiims for the interesting data and presentation of TALAPRO-2 trial. Talazoparib + Enzalutamide improve rPFS regardless HRR status. However OS benefit is pending and toxicity is a critical issue (72% G3/4 AE, 19% treatment discontinuation)… @OncologyBio #GU23
Fernando Sabino, MD, PhD tweet mediaFernando Sabino, MD, PhD tweet media
English
0
4
15
926
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
It still intriguing the positivity data from the non-HRR patients. Another important point is how these data are important for patients receiving a NHT in the mCSPC setting #GU23 @OncologyBio
Sumanta K. Pal, MD, FASCO@montypal

Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!

English
0
4
8
626
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
Interesting data, but how many patients were PSA persistent (RTOG) and how many relapse after 6 months (GETUG-16)? Radical-HD has a mixture of them. How PSMA PET would change the stage in a high risk population? #GU23 @OncologyBio
Yüksel Ürün@DrYukselUrun

Paul L. Nguyen @DanaFarber @BrighamWomens FORMULA-509: AAP/Apa to SRT+6 months of ADT may improve PFS and MFS, particularly in the subgroup of patients with PSA>0.5 #GU23 @ASCO @OncoAlert @urotoday @PCFnews @OncBrothers @APCCC_Lugano @HemOncFellows #prostatecancer

English
0
3
9
994
BIO - Brazilian Information Oncology retweetledi
Fernando Sabino, MD, PhD
Fernando Sabino, MD, PhD@fsabino_onco·
Provocative and pragmatic discussion of @Ecastromarcos regarding the data of TALAPRO-2 and TRITON-3 trials presented at ASCO #GU23. A final useful message/slide with all PARPi in different mCRPC treatment setting/scenario. @OncologyBio
Fernando Sabino, MD, PhD tweet media
English
0
6
14
1.1K
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
A very important and practical question is: does have any patient who failed to ADT plus NHT in mHSPC that deserve PARPi combinations in the mCRPC scenario? #GU23 @OncologyBio
Arun Azad@AzadOncology

Noel Clarke presenting PROpel OS data @ASCO #GU23 Improvement in OS of 7 months in ITT population largely driven by HRRm pts Need longer-term FU to see where OS lands in HRRm Vs non-HRR @OncoAlert @gu_onc @urotoday @Larvol

English
0
1
5
398
BIO - Brazilian Information Oncology retweetledi
Andrey Soares
Andrey Soares@SoaresAndrey·
Interesting OS curve from PROPEL with a separation after 22 months, coincident with the rPFS. Is the post-progression therapy influencing this data? #GU23 @OncologyBio
Andrey Soares tweet media
English
1
3
21
1.5K

Keşfet

@DrAndreFay @asasse @FabioSchutz78 @adrigons @DanielVargas_ @fsabino_onco @danielvargas_ @ASCO